Esophageal and Gastroesophageal Junction Carcinoma

Observed

← altered in cohorts of

EFR3A

133 / 185 cases (72 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

HHLA1

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

KHDRBS3

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRRC6

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

NDRG1

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

OC90

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLA

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ZFAT

132 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

PHF20L1

131 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ST3GAL1

131 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

TMEM71

131 / 185 cases (71 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ACTRT3

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

BCHE

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRRC31

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRRIQ4

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

NCEH1

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

PDCD10

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SAMD7

130 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

EIF5A2

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

FAM135B

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

FNDC3B

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRRC34

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MYNN

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

PHC3

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

RPL22L1

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SEC62

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLC14A1

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLC14A2

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLC2A2

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLC7A14

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLITRK3

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ST8SIA5

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

TNIK

129 / 185 cases (70 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ADGRB1

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

AGO2

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ARC

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

CLDN11

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

EPPK1

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

GML

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

GPR160

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LOXHD1

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

LRRC14

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ME2

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MECOM

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MELTF

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MEX3C

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MROH6

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

MTAP

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

PLD1

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

PRKCI

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

RNF165

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SERPINI1

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SKIL

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

SLURP2

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

TMEM212

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

TNFSF10

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

TNK2

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ZBBX

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

ZNF623

128 / 185 cases (69 %) · ssm · TCGA-ESCA

—

Observed

← altered in cohorts of

FER1L6

299 / 443 cases (67 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

MYC

296 / 443 cases (67 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

POU5F1B

294 / 443 cases (66 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

ASAP1

293 / 443 cases (66 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

DDX27

292 / 443 cases (66 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

COL14A1

290 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZNF831

290 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

GSDMC

289 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

NFATC2

289 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ANXA13

288 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

KLHL38

288 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

WASHC5

288 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

ATAD2

287 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

EXT1

287 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

FAM91A1

287 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

FBXO32

287 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

LRATD2

287 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

SQLE

287 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

ADNP

286 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

DCSTAMP

286 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ESRP1

286 / 443 cases (65 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

KCNV1

286 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

SNTB1

286 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZMYND8

286 / 443 cases (65 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

CYRIB

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

MTSS1

285 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

NSMCE2

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

RNF139

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

TAF2

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

TNFRSF11B

285 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

TRIB1

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

TRMT12

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

VIRMA

285 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZHX1

285 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZNF217

285 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZNF572

285 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

COL22A1

284 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

COLEC10

284 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

DCAF13

284 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

FZD6

284 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

GDF6

284 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

TATDN1

284 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

ZFPM2

284 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZHX2

284 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ANGPT1

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

DEPTOR

283 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

DPYS

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

DSCC1

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

KLF10

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

MAL2

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

MTBP

283 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

NDUFB9

283 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

OXR1

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

POP1

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

RGS22

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

SYBU

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

TMEM65

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZNFX1

283 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ABRA

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ATP9A

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

C8orf76

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

CCN3

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

CCN4

282 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

CTHRC1

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ENPP2

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

FAM83A

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

HAS2

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

KCNQ3

282 / 443 cases (64 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

NTAQ1

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

SAMD12

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

TSHZ2

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ZHX1-C8orf76

282 / 443 cases (64 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ARFGEF2

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

ATP6V1C1

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

GNAS

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

KCNB1

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

KCNS2

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

MRPL13

281 / 443 cases (63 %) · ssm · TCGA-STAD · largest of 2 cohorts

—

Observed

← altered in cohorts of

NCALD

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

NUDCD1

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

OSR2

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

PTDSS1

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

RSPO2

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

SLC30A8

281 / 443 cases (63 %) · ssm · TCGA-STAD

—

Observed

← altered in cohorts of

TP53

309 / 518 cases (60 %) · ssm · stes_tcga_pub · largest of 19 cohorts

—

Observed

← altered in cohorts of

TTN

276 / 518 cases (53 %) · ssm · stes_tcga_pub · largest of 16 cohorts

—

Observed

← altered in cohorts of

MUC16

171 / 518 cases (33 %) · ssm · stes_tcga_pub · largest of 12 cohorts

—

Observed

← altered in cohorts of

SYNE1

134 / 518 cases (26 %) · ssm · stes_tcga_pub · largest of 11 cohorts

—

Observed

← altered in cohorts of

LRP1B

125 / 518 cases (24 %) · ssm · stes_tcga_pub · largest of 10 cohorts

—

Observed

← altered in cohorts of

CSMD3

121 / 518 cases (23 %) · ssm · stes_tcga_pub · largest of 10 cohorts

—

Observed

← altered in cohorts of

FLG

108 / 518 cases (21 %) · ssm · stes_tcga_pub · largest of 9 cohorts

—

Observed

← altered in cohorts of

ARID1A

106 / 518 cases (20 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

CSMD1

104 / 518 cases (20 %) · ssm · stes_tcga_pub · largest of 10 cohorts

—

Observed

← altered in cohorts of

OBSCN

104 / 518 cases (20 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

PCLO

103 / 518 cases (20 %) · ssm · stes_tcga_pub · largest of 9 cohorts

—

Observed

← altered in cohorts of

DNAH5

99 / 518 cases (19 %) · ssm · stes_tcga_pub · largest of 9 cohorts

—

Observed

← altered in cohorts of

FAT4

99 / 518 cases (19 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

RYR2

98 / 518 cases (19 %) · ssm · stes_tcga_pub · largest of 8 cohorts

—

Observed

← altered in cohorts of

HMCN1

92 / 518 cases (18 %) · ssm · stes_tcga_pub · largest of 9 cohorts

—

Observed

← altered in cohorts of

KMT2D

91 / 518 cases (18 %) · ssm · stes_tcga_pub · largest of 11 cohorts

—

Observed

← altered in cohorts of

FAT3

88 / 518 cases (17 %) · ssm · stes_tcga_pub · largest of 9 cohorts

—

Observed

← altered in cohorts of

SPTA1

86 / 518 cases (17 %) · ssm · stes_tcga_pub · largest of 8 cohorts

—

Observed

← altered in cohorts of

TSPOAP1

46 / 295 cases (16 %) · ssm · stad_tcga_pub

—

Observed

← altered in cohorts of

ZFHX4

80 / 518 cases (15 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

USH2A

79 / 518 cases (15 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

PIK3CA

77 / 518 cases (15 %) · ssm · stes_tcga_pub · largest of 8 cohorts

—

Observed

← altered in cohorts of

PCDH15

76 / 518 cases (15 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

RYR3

74 / 518 cases (14 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

LRRK2

72 / 518 cases (14 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

SACS

72 / 518 cases (14 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

DNAH11

71 / 518 cases (14 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

DNAH7

70 / 518 cases (14 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

MUC12

24 / 185 cases (13 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

AHNAK2

67 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

DMD

67 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

MUC4

67 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 4 cohorts

—

Observed

← altered in cohorts of

NBEA

67 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

CUBN

66 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

HSPG2

66 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 4 cohorts

—

Observed

← altered in cohorts of

KMT2C

66 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

XIRP2

66 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

ADGRV1

65 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

DNAH9

65 / 518 cases (13 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

APOB

64 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

SYNE2

63 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

ANK3

62 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

DOCK3

62 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 4 cohorts

—

Observed

← altered in cohorts of

PLEC

62 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

RYR1

62 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

PSME4

35 / 295 cases (12 %) · ssm · stad_tcga_pub

—

Observed

← altered in cohorts of

LAMA1

61 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

MUC5B

61 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

NEB

61 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

ERBB4

60 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

MUC17

60 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

← altered in cohorts of

PKHD1L1

60 / 518 cases (12 %) · ssm · stes_tcga_pub · largest of 7 cohorts

—

Observed

← altered in cohorts of

ZNF43

34 / 295 cases (12 %) · ssm · stad_tcga_pub

—

Observed

← altered in cohorts of

COL12A1

59 / 518 cases (11 %) · ssm · stes_tcga_pub · largest of 5 cohorts

—

Observed

← altered in cohorts of

DNAH3

59 / 518 cases (11 %) · ssm · stes_tcga_pub · largest of 4 cohorts

—

Observed

← altered in cohorts of

DST

59 / 518 cases (11 %) · ssm · stes_tcga_pub · largest of 6 cohorts

—

Observed

Esophageal and Gastroesophageal Junction Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)
→ investigated in trials for	Fluorouracilsmall molecule 98 trials (41 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	98	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 96 trials (45 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 96 trials (44 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 80 trials (28 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	80	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 76 trials (26 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	76	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 66 trials (32 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 52 trials (20 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 48 trials (15 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 48 trials (22 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 38 trials (20 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 36 trials (19 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 35 trials (21 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 30 trials (17 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 27 trials (10 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 27 trials (14 active) · roll-up of the cancer and its descendants	—	—	Esophageal and Gastroesophageal Junction Carcinoma	27	Observed	clinicaltrials	graph →

Esophageal and Gastroesophageal Junction Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)

→ investigated in trials for

Fluorouracilsmall molecule

98 trials (41 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

96 trials (45 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

96 trials (44 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

80 trials (28 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

76 trials (26 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

66 trials (32 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

52 trials (20 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

48 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

48 trials (22 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

38 trials (20 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

36 trials (19 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

35 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumabmonoclonal antibody

30 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ramucirumabmonoclonal antibody

27 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

27 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

Esophageal and Gastroesophageal Junction Carcinoma studied in …STUDIED_INderived10 of 1,309show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07529808Phase 1/Phase 2 · recruiting Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03030404completed Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped ALIAS · 1,309 trials mapped (550 active)	—	—	Hereditary Gastric Diffuse Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07733180Phase 2 · recruiting A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)	—	—	Esophageal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Esophageal and Gastroesophageal Junction Carcinoma studied in …STUDIED_INderived10 of 1,309show all (up to 200)

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT06203600Phase 2/Phase 3 · recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT07212491enrolling by invitation

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT07529808Phase 1/Phase 2 · recruiting

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT07603375Phase 2 · recruiting

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

Hereditary Gastric Diffuse Adenocarcinoma

→ studied in

NCT03030404completed

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer · condition mapped ALIAS · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT05965999recruiting

Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT07277413Phase 1 · recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

→ studied in

NCT07392892Phase 2/Phase 3 · recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 1,309 trials mapped (550 active)

—

Observed

Esophageal Squamous Cell Carcinoma

→ studied in

NCT07733180Phase 2 · recruiting

A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC · condition mapped CURATED_BROADER · 1,309 trials mapped (550 active)

—

Observed